| Schedule of discontinued operations |
| | | | | | | | | 2025 | | 2024 | | 2023 | Other income | | — | | 38,401 | | 29,881 | Research and development | | — | | (1,337,936) | | (5,716,857) | General and administration | | — | | (673,259) | | (2,351,356) | Total operating costs | | — | | (2,011,195) | | (8,068,213) | | | | | | | | Operating loss | | — | | (1,972,794) | | (8,038,332) | | | | | | | | Finance expense | | — | | (5,672) | | (17,742) | Net loss before tax | | — | | (1,978,466) | | (8,056,074) | Income tax expense | | — | | — | | — | Net loss from discontinued operations | | — | | (1,978,466) | | (8,056,074) | Net gain / (loss) of the sale of activities after income tax | | 114,342 | | 13,943,595 | | — | Total net gain / (loss) from Discontinued operations | | 114,342 | | 11,965,129 | | (8,056,074) |
| | | | | | | | | 2025 | | 2024 | | 2023 | Staff costs | | — | | 1,422,182 | | 5,138,331 | Depreciation | | — | | 67,422 | | 294,200 | External research and development cost | | — | | 333,278 | | 1,805,708 | Laboratory consumables | | — | | 17,735 | | 331,279 | Patent maintenance and registration costs | | — | | 62,563 | | 140,906 | Professional fees | | — | | 38,271 | | — | Short-term leases | | — | | 8,329 | | 35,130 | Other operating costs | | — | | 61,415 | | 322,659 | Total discontinued operating costs | | — | | 2,011,195 | | 8,068,213 |
| | | | | | | | | 2025 | | 2024 | | 2023 | Net profit / (loss) from discontinued operations | | 114,342 | | 11,965,129 | | (8,056,074) | Adjustments for: | | | | | | | Net gain on Neurosterix Transaction | | (114,342) | | (13,943,595) | | — | Value of share-based services | | — | | 327,681 | | 1,514,267 | Post-employment benefits | | — | | (27,338) | | (61,238) | Depreciation | | — | | 67,422 | | 294,200 | Net gain related to lease modifications | | — | | — | | (318) | Finance cost net | | — | | 5,672 | | 17,742 | Decrease in trade and other receivables | | — | | 12,702 | | 111,829 | Decrease / (increase) in prepayments | | — | | (151,695) | | 26,065 | Increase in other current assets | | — | | (7,967) | | — | Increase / (decrease) in payables and accruals | | — | | (811,126) | | 5,059 | Increase / (decrease) in deferred income | | — | | (38,401) | | 324,210 | Net cash flow used in operating activities | | — | | (2,601,516) | | (5,824,258) | | | | | | | | Net cash flow from / (used in) investing activities | | | | | | | Consideration from Neurosterix Transaction | | 114,342 | | 5,119,754 | | — | Legal fees paid for Neurosterix Transaction | | — | | (473,270) | | — | Purchase of property, plant and equipment | | — | | — | | (6,842) | Net cash from / (used) in investing activities | | 114,342 | | 4,646,484 | | (6,842) | | | | | | | | Cash flows used in financing activities | | | | | | | Principal element of lease payment | | — | | (63,772) | | (270,294) | Interest paid | | — | | (5,672) | | (17,742) | Net cash used in financing activities | | — | | (69,444) | | (288,036) | | | | | | | | Net cash from / (used in) discontinued activities | | 114,342 | | 1,975,524 | | (6,119,136) |
| | | | | | | 2025 | | 2024 | Consideration received | | | | | Cash in from Neurosterix Pharma Sàrl sale | | — | | 5,000,000 | Fair value of Neurosterix US Holdings LLC’s participation | | — | | 9,428,400 | Net gain on Neurosterix Pharma Sàrl derecognition (IFRS10) | | — | | 539,250 | Retirement benefit obligation of employees leaving the Group (IAS 19) (note 20) | | — | | 433,791 | Fair value of service agreement | | — | | 182,348 | Net debt liabilities related to Neurosterix Pharma Sàrl (IFRS 16) | | — | | 11,144 | Other consideration | | 114,342 | | — | Total Disposal consideration | | 114,342 | | 15,594,933 | | | | | | Investment in Neurosterix Pharma Sàrl | | — | | (20,000) | Legal fees paid for Neurosterix Transaction | | — | | (473,269) | Accelerating vesting ESOP/DSPPP | | — | | (1,158,069) | Total costs related to activities sold | | — | | (1,651,338) | | | | | | Net gain on sale before income tax | | 114,342 | | 13,943,595 | | | | | | Income tax expense on gain | | — | | — | Net gain on sale after income tax | | 114,342 | | 13,943,595 |
|